Market News AIOpen the app

RLAY stock news · Elevar Therapeutics

Stories about Elevar Therapeutics (RLAY) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for RLAY

Follow Elevar Therapeutics (RLAY) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for RLAY
Free on the App Store and Google Play, or on the web.
  1. Nov 3, 2026, 7:08 PM ET · Market

    Elevar Therapeutics' drug lirafugratinib is now included in important U.S. treatment guidelines.

    Good for RLAY

    Relay Therapeutics' lirafugratinib, licensed to Elevar, was added to NCCN cancer-care guidelines as a Category 2A recommendation. U.S. availability is expected in Q4 2026, supporting RLAY's prospects.